454 related articles for article (PubMed ID: 26598957)
1. Overview of current immunotherapeutic strategies for glioma.
Calinescu AA; Kamran N; Baker G; Mineharu Y; Lowenstein PR; Castro MG
Immunotherapy; 2015; 7(10):1073-104. PubMed ID: 26598957
[TBL] [Abstract][Full Text] [Related]
2. Advances in Immunotherapy for Glioblastoma Multiforme.
Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium.
Kim ES; Kim JE; Patel MA; Mangraviti A; Ruzevick J; Lim M
J Immunol Res; 2016; 2016():4683607. PubMed ID: 26881264
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
Mathios D; Park CK; Marcus WD; Alter S; Rhode PR; Jeng EK; Wong HC; Pardoll DM; Lim M
Int J Cancer; 2016 Jan; 138(1):187-94. PubMed ID: 26174883
[TBL] [Abstract][Full Text] [Related]
5. Recent advances and future of immunotherapy for glioblastoma.
Kamran N; Calinescu A; Candolfi M; Chandran M; Mineharu Y; Asad AS; Koschmann C; Nunez FJ; Lowenstein PR; Castro MG
Expert Opin Biol Ther; 2016 Oct; 16(10):1245-64. PubMed ID: 27411023
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy and radiation in glioblastoma.
Sahebjam S; Sharabi A; Lim M; Kesarwani P; Chinnaiyan P
J Neurooncol; 2017 Sep; 134(3):531-539. PubMed ID: 28567588
[TBL] [Abstract][Full Text] [Related]
7. Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.
Xiong Z; Ampudia-Mesias E; Shaver R; Horbinski CM; Moertel CL; Olin MR
Immunotherapy; 2016 Sep; 8(9):1059-71. PubMed ID: 27485078
[TBL] [Abstract][Full Text] [Related]
8. How immunotherapies are targeting the glioblastoma immune environment.
Felthun J; Reddy R; McDonald KL
J Clin Neurosci; 2018 Jan; 47():20-27. PubMed ID: 29042147
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma antigen discovery--foundations for immunotherapy.
Azad TD; Razavi SM; Jin B; Lee K; Li G
J Neurooncol; 2015 Jul; 123(3):347-58. PubMed ID: 26045361
[TBL] [Abstract][Full Text] [Related]
10. Immunological challenges for peptide-based immunotherapy in glioblastoma.
Mohme M; Neidert MC; Regli L; Weller M; Martin R
Cancer Treat Rev; 2014 Mar; 40(2):248-58. PubMed ID: 24064197
[TBL] [Abstract][Full Text] [Related]
11. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
Front Immunol; 2020; 11():582106. PubMed ID: 33178210
[TBL] [Abstract][Full Text] [Related]
12. Challenges in clinical design of immunotherapy trials for malignant glioma.
Rolle CE; Sengupta S; Lesniak MS
Neurosurg Clin N Am; 2010 Jan; 21(1):201-14. PubMed ID: 19944979
[TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy in brain tumors].
De Carli E; Delion M; Rousseau A
Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapeutic approaches for glioma.
Okada H; Kohanbash G; Zhu X; Kastenhuber ER; Hoji A; Ueda R; Fujita M
Crit Rev Immunol; 2009; 29(1):1-42. PubMed ID: 19348609
[TBL] [Abstract][Full Text] [Related]
15. Current challenges in designing GBM trials for immunotherapy.
Weathers SP; Gilbert MR
J Neurooncol; 2015 Jul; 123(3):331-7. PubMed ID: 25577401
[TBL] [Abstract][Full Text] [Related]
16. Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.
Genoud V; Migliorini D
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800593
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
18. Toward a glioblastoma vaccine: promise and potential pitfalls.
Fine HA
J Clin Oncol; 2004 Nov; 22(21):4240-3. PubMed ID: 15452184
[No Abstract] [Full Text] [Related]
19. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.
Steiner HH; Bonsanto MM; Beckhove P; Brysch M; Geletneky K; Ahmadi R; Schuele-Freyer R; Kremer P; Ranaie G; Matejic D; Bauer H; Kiessling M; Kunze S; Schirrmacher V; Herold-Mende C
J Clin Oncol; 2004 Nov; 22(21):4272-81. PubMed ID: 15452186
[TBL] [Abstract][Full Text] [Related]
20. Exploitation of immune mechanisms in the treatment of central nervous system cancer.
Pollack IF; Okada H; Chambers WH
Semin Pediatr Neurol; 2000 Jun; 7(2):131-43. PubMed ID: 10914414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
